GSK to pay Chimagen $300m upfront to develop autoimmune drug
GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs
Health
Medical